BGIM
COLL icon

Brandywine Global Investment Management’s Collegium Pharmaceutical COLL Stock Holding History

Brandywine Global Investment Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.04M Sell
130,545
-4,800
-4% -$201K 0.04% 344
2025
Q3 		$4.74M Sell
135,345
-5,018
-4% -$174K 0.03% 384
2025
Q2 		$4.15M Buy
140,363
+25,600
+22% +$730K 0.03% 401
2025
Q1 		$3.43M Buy
114,763
+13,792
+14% +$421K 0.02% 413
2024
Q4 		$2.89M Sell
100,971
-149,402
-60% -$4.94M 0.02% 439
2024
Q3 		$9.51M Buy
250,373
+85,645
+52% +$3.05M 0.06% 273
2024
Q2 		$5.3M Sell
164,728
-41,686
-20% -$1.45M 0.04% 382
2024
Q1 		$8.01M Sell
206,414
-167,701
-45% -$5.87M 0.06% 315
2023
Q4 		$11.5M Sell
374,115
-9,226
-2% -$231K 0.09% 225
2023
Q3 		$8.57M Sell
383,341
-2,405
-0.6% -$54.9K 0.08% 262
2023
Q2 		$8.29M Buy
385,746
+11,133
+3% +$253K 0.07% 276
2023
Q1 		$8.99M Buy
374,613
+4,935
+1% +$131K 0.07% 262
2022
Q4 		$8.58M Buy
369,678
+44,416
+14% +$896K 0.07% 261
2022
Q3 		$5.21M Buy
325,262
+54,012
+20% +$952K 0.05% 322
2022
Q2 		$4.81M Buy
271,250
+28,490
+12% +$479K 0.04% 365
2022
Q1 		$4.94M Buy
242,760
+2,538
+1% +$48K 0.04% 395
2021
Q4 		$4.49M Buy
240,222
+156,849
+188% +$3.06M 0.03% 421
2021
Q3 		$1.65M Buy
83,373
+4,636
+6% +$100K 0.01% 544
2021
Q2 		$1.86M Sell
78,737
-5,205
-6% -$120K 0.01% 542
2021
Q1 		$1.99M Sell
83,942
-708
-0.8% -$16.8K 0.02% 524
2020
Q4 		$1.7M Sell
84,650
-5,236
-6% -$102K 0.01% 497
2020
Q3 		$1.87M Buy
89,886
+14,105
+19% +$255K 0.02% 462
2020
Q2 		$1.33M Buy
75,781
+744
+1% +$14.6K 0.01% 494
2020
Q1 		$1.23M Buy
75,037
+489
+0.7% +$10.1K 0.01% 502
2019
Q4 		$1.61M Buy
74,548
+11,981
+19% +$200K 0.01% 541
2019
Q3 		$719K Buy
+62,567
New +$714K 0.01% 579
2018
Q1 		– Sell
-105,376
Closed -$1.95M – 905
2017
Q4 		$1.95M Sell
105,376
-11,623
-10% -$166K 0.01% 553
2017
Q3 		$1.23M Buy
+116,999
New +$1.29M 0.01% 578

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brandywine Global Investment Management's COLL Position: Q4 2025 in Review

Brandywine Global Investment Management reduced its Collegium Pharmaceutical (COLL) stake by 3.5% in Q4 2025, selling an estimated $201K and leaving 130,545 shares worth $6.04M. The position accounts for 0.04% of the portfolio, ranked #344.

Brandywine Global Investment Management first reported a position in COLL in Q3 2017 and has held it in 28 quarters since. The position peaked at $11.5M in Q4 2023. 278 funds tracked by Wall St. Rank hold COLL as of Q4 2025.

  • Brandywine Global Investment Management held 130,545 shares of Collegium Pharmaceutical worth $6.04M as of Q4 2025.
  • Brandywine Global Investment Management sold 4,800 Collegium Pharmaceutical shares in Q4 2025, an estimated $201K.
  • Collegium Pharmaceutical made up 0.04% of Brandywine Global Investment Management's portfolio in Q4 2025, its #344 holding.
  • Brandywine Global Investment Management first reported a position in Collegium Pharmaceutical in Q3 2017 and has held it in 28 quarters since.
  • Brandywine Global Investment Management's Collegium Pharmaceutical position peaked at $11.5M in Q4 2023.
  • 278 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2025.

Based on Brandywine Global Investment Management's 13F filing for Q4 2025, filed 11 Feb 2026.